Stereotaxis (AMEX:STXS) and Neusoft Medical Systems Co., Ltd have announced that Stereotaxis’ cutting-edge GenesisX robotic system is being debuted at Neusoft Medical Systems’ booth at the Radiology Society of North America’s (RSNA) 2024 Annual Meeting, which is ongoing from December 1-5 in Chicago, IL.
RSNA stands as the world’s premier annual radiology forum, drawing over 50,000 attendees from more than 150 countries. Neusoft Medical Systems is recognized as a global leader in advanced medical imaging solutions, with an impressive portfolio of over 47,000 installed systems that ensure high-quality care to patients and healthcare providers worldwide. The showcase includes Stereotaxis’ GenesisX System, the latest breakthrough in endovascular robotics, alongside Neusoft Medical Systems’ NeuAngio 30F fluoroscopy system.
The presence of these technological advancements at RSNA reflects the burgeoning collaboration between Stereotaxis and Neusoft Medical Systems in integrating and commercializing complementary technologies. GenesisX builds on the robust foundations of Robotic Magnetic Navigation technology, aiming to reduce complexities and barriers in hospital adoption. This system is crafted to enhance precision, efficiency, and safety across a diverse range of endovascular procedures.
“Neusoft Medical Systems is committed to providing advanced high-quality medical technologies that improve healthcare globally,” stated Patrick Wu, CEO of Neusoft Medical Systems. “Stereotaxis’ revolutionary GenesisX robotic technology aligns well with our portfolio of advanced innovative imaging systems, and we are pleased to collaborate with Stereotaxis to showcase our joint solutions at RSNA 2024.”
“We very much appreciate the invitation by Neusoft Medical Systems to demonstrate GenesisX at RSNA and are excited to showcase our joint technologies for the first time at a conference of this caliber,” expressed David Fischel, CEO of Stereotaxis. “GenesisX promises to have a profound impact on the trajectory of endovascular robotics. We look forward to our expanded collaboration with Neusoft Medical Systems in delivering groundbreaking technologies to patients globally.”
Stereotaxis (AMEX:STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission spans the discovery, development, and delivery of robotic systems, instruments, and information solutions tailored for the interventional laboratory. These innovations empower physicians to deliver unparalleled patient care with robotic precision and safety, expand access to minimally invasive therapy, and boost productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been employed to treat over 150,000 patients across the United States, Europe, Asia, and beyond.
With the collaboration between Stereotaxis and Neusoft Medical Systems, health care professionals and patients worldwide can anticipate access to advanced, accurate, and efficient robotic medical solutions, promising a new era in endovascular procedure technology.
At RSNA, the showcase of GenesisX alongside Neusoft’s NeuAngio 30F fluoroscopy system exemplifies a shared vision of advancing medical technology and improving health care standards on a global scale. The GenesisX robotic system marks a significant milestone in the field, reinforcing the promise of robotic collaboration and integration in medical imaging and surgical intervention.
Attendees of RSNA 2024 have the exclusive opportunity to explore these joint solutions and understand the potential impacts of these innovations firsthand. This collaboration underscores the commitment of both companies to revolutionize healthcare through strategic partnerships and pioneering technology.
The future of medical robotics and imaging solutions is brighter with the introduction of the GenesisX System, and its presence at RSNA represents a critical step toward the worldwide adoption of sophisticated medical technologies that aim to elevate patient care and operational efficiency in healthcare facilities.